FDA Recalls Dexamethasone Injectable Vials Due to Sterility Concerns
Oregon Compounding Centers is recalling Dexamethasone injectable vials due to quality control issues affecting sterility assurance identified during an FDA inspection.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, FDA Class II recalls with potential for significant injury or hospitalization (implied by sterility failure in injectables) are rated as Severe (4).
Plain-English summary
The U.S. Food and Drug Administration (FDA) has issued a Class II recall for Dexamethasone (as Sod Phos), 24 mg/mL, injectable, 1 mL glass vials manufactured by Oregon Compounding Centers, Inc. dba Creative Compounds. The recall involves all lots of sterile products compounded by the pharmacy that have not expired.
The recall was initiated due to concerns regarding quality control procedures that present a potential risk to sterility assurance. These issues were observed during a recent FDA inspection of the facility. The specific lot number 20140903@10 with a discard date of 10/18/2014 is identified in the product information, but the recall scope includes all non-expired sterile lots from the pharmacy.
The affected products were distributed in Oregon and Washington. Consumers and healthcare providers should stop using these products and contact their healthcare provider or the recalling firm for further instructions. The FDA classifies this as a Class II recall, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- DEXAMETHASONE (AS SOD PHOS), 24 mg/mL, injectable, 1 mL glass vial, RX, Creative Compounds, Wilsonville, OR 97070
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 20140903@10
- discard date: 10/18/2014
Distribution
Part of a larger recall action
This product is one of 56 recalled by Oregon Compounding Centers, Inc. dba Creative Compounds under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 56 products in this recall →Related recalls
Same manufacturer · Oregon Compounding Centers, Inc. dba Creative Compounds
See all →- SevereGanciclovir Syringes Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Papaverine Injectable Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Injectable Methycobalamin Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereCreative Compounds Recalls Ceftazidime Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-11-12
- SevereFDA Recalls Vitamin B Complex Injectable Due to Sterility Concerns
FDA (Drugs) · 2014-11-12
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22